|
Patent landscape, scope, and claims: |
Scope and Patent Landscape Analysis for U.S. Patent 4,863,737 (Drug-Containing Lollipops for Transmucosal Delivery)
U.S. Patent 4,863,737 claims a compressed “drug-in-confectionary-matrix” lollipop platform for transmucosal delivery to the mouth/pharynx/esophagus. The tightest scope is the combination of (i) substantially powdered, mucosally absorbable drug dispersed uniformly through a soluble, compressible carbohydrate matrix, (ii) mixing and compression at temperatures below melting points, (iii) dissolution-based release in the mouth, and (iv) a holder integrated into the integral mass. Dependent claim sets broaden coverage into buffers that tune drug ionization (citric acid/sodium citrate), excipient functions (lubricants, flavor enhancers, maltodextrin), controlled dissolution using water-insoluble components, and explicit drug exemplars (methohexital, nitroglycerin, benzodiazepines, etc.). The landscape is best characterized as a “core platform claim” with multiple drug-specific and formulation-option fallbacks that support both licensing leverage and generic/formulation entry risk for oral transmucosal lollipop products that practice the same matrix architecture.
What are the independent and dependent claims scope for U.S. Patent 4,863,737?
Claim 1 (independent, method): Producing a drug-containing lollipop for transmucosal delivery, requiring all elements below in combination:
- Drug: pharmacologically effective dose in substantially powdered form, capable of absorption through mucosal tissues of the mouth, pharynx, and esophagus.
- Carbohydrate matrix: soluble, compressible confectionary material capable of forming a compressible matrix and dissolving in the mouth.
- Mixing condition: mix drug + carbohydrate at a temperature below the melting points of both components.
- Dispersion + release: drug dispersed substantially throughout the matrix; upon dissolution, drug released for mucosal absorption.
- Compression: compress the drug-containing matrix in a mold into an integral mass.
- Holder: incorporate a holder as part of the integral mass to form the lollipop.
Claim 6 (independent, composition): A lollipop composition with analogous structural/functional limitations:
- Soluble, compressible, substantially powdered carbohydrate material
- Powdered lipophilic drug dispersed substantially uniformly
- Buffer (pKa modifier) dispersed substantially uniformly and configured to keep a majority non-ionized to facilitate transmucosal absorption
- Holder means secured to the integral mass, configured for insertion/removal
Claim 18 (independent, method, dose-to-effect): Adds a “dose-to-effect manner” requirement:
- drug is substantially powdered lipophilic and mucosally absorbable
- buffer capable of modifying pKa so a majority is non-ionized
- steps similar to claim 1 but framed around delivering a dose-to-effect response
How to read the claim architecture
- The patent is not only about “lollipops.” It is about a specific manufacturing and formulation logic: powdered drug + soluble compressible candy matrix + mixing below melting + uniform dispersion + compression into a dissolvable integral mass + holder integration. The buffer/pKa and dissolution-rate levers are additive dependent claim features.
What formulations are covered: buffer/pKa tuning, lubricants, dissolution retarders, flavor, and dose ranges?
Buffer and pKa control (ionization management)
Key dependent claims:
- Claim 2: buffer added to drug-containing matrix.
- Claim 3: buffer modifies pKa so majority drug remains non-ionized for transmucosal absorption.
- Claim 4: buffer is citric acid/sodium citrate.
- Claim 18 and claim 22: buffer-based dose-to-effect method; buffer comprises citric acid/sodium citrate.
- Claim 37-38: composition claim includes buffer dispersed through integral mass; citric acid/sodium citrate.
Practical scope takeaway:
- Buffer claims are not generic “buffering.” They are mechanistically constrained to pKa modification and non-ionized majority.
Water-insoluble component for slower dissolution
- Claim 13: substantially water-insoluble component slows dissolution.
- Claim 36: water-insoluble component used as releasing agent to slow dissolution.
- Claim 43: composition includes substantially water-insoluble component to slow dissolution.
Lubricants and mold release
- Claim 10: lubricating agent to release from mold.
- Claim 34: lubricating agent present for release.
- Claim 35: lubricating agent comprises glyceryl behenate.
Flavor masking and palatability excipients
- Claim 11: flavor enhancer included in matrix.
- Claim 12: maltodextrin aids in dissipating unpleasant flavors.
- Claim 21: maltodextrin in dose-to-effect method for matrix production.
- Claims 24, 25, 41, 42, 44, 45, 48, 49, 51, 52 expand flavor and excipient combinations:
- flavoring ingredient or flavor enhancer mixing steps
- composition flavoring dispersed in integral mass
- sweetener option in addition to carbohydrate material
Compression force range
- Claim 14: compressive forces ~2000 to 5000 newtons.
This is a process-parameter limitation. If an accused process omits the specific range or uses different compression engineering, infringement analysis shifts from “core architecture” to a narrower technical overlap.
Explicit drug exemplars (species coverage)
Claim 15: methohexital
Claim 16: triazolan, oxazepam, lorazepam, etomidate, thiamylal
Claim 17: nitroglycerin
Dose-to-effect method species:
- Claims 26-27: methohexital; then the benzodiazepine and related group
- Claim 28: isosorbide dinitrate, captopril, nifedipine, clonidine, esimolol
- Claim 29: nitroglycerin
- Claims 30-33: potent fast-acting drugs; effects categorized as CNS, cardiovascular, renal vascular
What is the effective “platform” claim overlap across method and composition claims?
The platform overlap is anchored by the repeated combination of:
- Powdered mucosally absorbable drug
- Soluble compressible carbohydrate confectionary matrix
- Mixing below melting points
- Uniform dispersion of drug through matrix
- Compression into an integral mass
- Holder integrated to form the lollipop
- Dissolution in mouth releases drug for mucosal absorption
Then the patent layers dependent features:
- Buffer/pKa tuning (claims 2-4; 18; 22; 37-38)
- Lubricant and mold release (claims 10; 34-35)
- Dissolution rate control using water-insoluble component (claims 13; 36; 43)
- Palatability excipients (maltodextrin, flavor enhancers, flavoring)
- Compression force range (claim 14 and claim 25)
- Drug-specific examples and dose ranges (claims 15, 26, 46-47)
This creates a landscape where many competitors may practice “lollipop transmucosal delivery” broadly, but only those that satisfy the patent’s specific formulation/manufacturing constraints and optional buffer/ionization control elements face the highest infringement risk.
Where do the claims narrow the scope: pKa, non-ionized majority, lipophilicity, and “below melting points”?
The major narrowing hooks:
- pKa non-ionized majority: Claims 3, 18, 37 (and 38 by dependent reference) require that the buffer causes a majority of drug to remain non-ionized.
- Lipophilicity: Claim 6 uses “powdered lipophilic drug”; claim 18 includes powdered lipophilic form. Claim 1 and claim 2 do not explicitly require lipophilicity.
- Temperature constraint: Mixing at temperature below melting points of drug and carbohydrate. This excludes processes using melted candy mass or high-heat granulation that would melt or degrade actives.
- Uniform dispersion “substantially uniformly throughout”: affects formulation blending and whether drug is segregated, layered, or surface-adsorbed instead of dispersed.
How many distinct claim “feature clusters” exist, and which are most likely to drive infringement?
Using the provided claims, the distinct feature clusters are:
-
Core platform (claims 1, 6, 7-9, 37, 39-42, 43, 48-52)
- powdered drug + soluble compressible carbohydrate matrix + mixing below melting + uniform dispersion + compression into integral dissolvable mass + holder integration + dissolution releases drug.
-
Buffer and pKa tuning (claims 2-4, 18, 22, 37-38)
- buffer modifies pKa; majority non-ionized.
-
Dissolution slowing (claims 13, 36, 43, and “releasing agent” phrasing)
-
Manufacturing aids: lubricant/mold release (claims 10, 34-35)
-
Organoleptics: flavor enhancer, maltodextrin, flavoring (claims 11-12, 21, 24, 41-42, 44-45, 48-49, 51, 52)
-
Process parameter: compression force range (claims 14 and 25)
-
Drug species coverage and dose ranges (claims 15, 16, 17, 26-29, 30-33, 46-47)
- Some are process-step method claims; others are matrix/composition constraints including mg ranges.
Most infringement-driving cluster in practice is cluster (1), because it is the broadest and present in both method and composition. Cluster (2) becomes critical when a product uses a buffer strategy designed for non-ionized transmucosal absorption.
What patent estate strength can be inferred for U.S. Patent 4,863,737 from claim breadth alone?
On claim breadth, the estate appears strong for:
- Drug-in-candy matrix architecture for transmucosal delivery with a holder-integrated lollipop.
- Manufacturing recipe constraints (below melting points, uniform dispersion, compressible soluble matrix, integral mass dissolution).
It also has internal “claim stacking” that supports design-around stress:
- Even if a competitor avoids the buffer, they may still fall into the core platform claims (claim 1/6 elements without buffer).
- If a competitor avoids the specific buffer, they may still fall into core platform claims if they still use soluble compressible carbohydrate matrix, below-melting mixing, compression, and holder integration.
- If they avoid holder integration into the integral mass, dependent claims 7-8 and 19-20 leave room for infringement under core claim 1 (which already requires holder incorporated) while changing “incorporating method.” In other words, the holder feature is not merely optional or only in dependent form.
The explicit drug examples do not limit the independent claims to those drugs. Instead, the examples are embedded as dependent limitations for particular actives.
How strong is the patent coverage against generic entry for oral transmucosal lollipop products?
Risk is highest when a generic or follow-on product:
- uses a powdered active (not a liquid solution, not a melted dispersion),
- uses a soluble compressible carbohydrate matrix that dissolves in the mouth,
- mixes below melting points of active and carbohydrate,
- compresses into an integral dissolvable mass,
- integrates a holder as part of the integral mass, and
- (for higher-risk scenarios) uses a buffer that keeps a non-ionized majority for transmucosal absorption.
Key generic entry mitigations
- Avoiding the core architecture is harder than adjusting a dependent feature. In practical design-around terms, competitors must often change one of: carbohydrate matrix class, process thermal profile, drug dispersion state, integral mass dissolution behavior, or lollipop holder integration approach.
What would a claim chart “cover” for a potential competitor formulation?
A competitor practicing a conventional sugar-based lozenge/lollipop made by melting candy and pouring into a mold would likely fail the “temperature below melting points” limitation of claim 1. A competitor using a powdered blend pressed at controlled conditions and dissolving in mouth remains closer.
A competitor using a buffered formulation might still satisfy pKa/non-ionized majority. If they buffer but do not demonstrate non-ionized majority at use conditions, the buffer-specific claims narrow the infringement path.
A competitor using surface-coated powder on a matrix instead of “substantially uniformly dispersed throughout” also creates a non-infringing argument, though infringement would become fact-intensive.
What comparative competitive landscape can be built from the claim drug exemplars?
The exemplars indicate market-adjacent drug categories:
- Sedative/anxiolytic: methohexital; triazolan; oxazepam; lorazepam; thiamylal; etomidate
- Cardiovascular/nitrates: nitroglycerin; isosorbide dinitrate
- Antihypertensive/CNS-modulating: nifedipine; clonidine; captopril; esimolol
- Potent fast-acting drugs broadly across CNS, cardiovascular, renal vascular systems (claims 30-33)
This supports a landscape view that any company developing oral transmucosal “fast onset” dosage forms using pressed dissolvable sugar matrices faces a potential overlap, especially if the product uses powdered actives, uniform dispersion, and a holder integrated into the integral mass.
When does exclusivity end for U.S. Patent 4,863,737?
The user-provided text does not include filing date, priority date, prosecution history, or terminal disclaimer status. Without those, an accurate exclusivity or expiration date cannot be derived from the claims alone.
What litigation or FDA Orange Book status exists for this patent?
No Orange Book listing, FDA application number, marketing authorization status, or litigation docket details are included in the prompt. Without those, a precise litigation and regulatory landscape cannot be produced.
Key Takeaways
- U.S. Patent 4,863,737 is a lollipop platform patent centered on a pressed, dissolvable, soluble carbohydrate matrix loaded with powdered mucosally absorbable drug and holder-integrated integral mass.
- Independent coverage is in method claims (claim 1, claim 18) and a composition claim (claim 6), with the buffer/pKa “non-ionized majority” mechanism creating a high-value sub-scope.
- Dependent claims expand into citric acid/sodium citrate pKa tuning, lubricant/mold release (glyceryl behenate), dissolution slowing using water-insoluble components, and organoleptics (maltodextrin, flavor enhancers).
- The most infringement-damaging elements are the core recipe: below-melting mixing, uniform dispersion in a compressible soluble carbohydrate matrix, compression into an integral mass that dissolves in the mouth, and holder incorporation into that integral mass.
- Drug exemplars show the patent is positioned for fast-acting transmucosal drugs, but the independents are not limited to those specific compounds.
FAQs
- How do the claims treat sugar-based lozenges that are manufactured by melting candy rather than pressing powders?
- Does the presence of a buffer automatically infringe, or is “non-ionized majority” required?
- If a product uses a dissolvable matrix but does not integrate the holder into the compressed integral mass, does claim coverage remain?
- How do the claims distinguish “releasing agent” slow-dissolution additives from standard taste-masking excipients?
- Which elements of the method claims are most likely to be bypassed through process reformulation versus material substitution?
References
No external sources were provided or cited in the prompt.
More… ↓
⤷ Start Trial
|
